Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2016 / Article
Special Issue

New Exploration of Chinese Herbal Medicines in Hepatology

View this Special Issue

Research Article | Open Access

Volume 2016 |Article ID 8762345 | https://doi.org/10.1155/2016/8762345

Ning Wang, Qihe Xu, Hor Yue Tan, Ming Hong, Sha Li, Man-Fung Yuen, Yibin Feng, "Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells", Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 8762345, 11 pages, 2016. https://doi.org/10.1155/2016/8762345

Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells

Academic Editor: Victor Kuete
Received19 Jan 2016
Accepted15 Mar 2016
Published30 Apr 2016


Aim. To examine the effect of berberine (BBR) on liver fibrosis and its possible mechanisms through direct effects on hepatic stellate cells (HSC). Methods. The antifibrotic effect of BBR was determined in a rat model of bile duct ligation- (BDL-) induced liver fibrosis. Multiple cellular and molecular approaches were introduced to examine the effects of BBR on HSC. Results. BBR potently inhibited hepatic fibrosis induced by BDL in rats. It exhibited cytotoxicity to activated HSC at doses nontoxic to hepatocytes. High doses of BBR induced apoptosis of activated HSC, which was mediated by loss of mitochondrial membrane potential and Bcl-2/Bax imbalance. Low doses of BBR suppressed activation of HSC as evidenced by the inhibition of α-smooth muscle actin (α-SMA) expression and cell motility. BBR did not affect Smad2/3 phosphorylation but significantly activated 5′ AMP-activated protein kinase (AMPK) signalling, which was responsible for the transcriptional inhibition by BBR of profibrogenic factors α-SMA and collagen in HSC. Conclusion. BBR is a promising agent for treating liver fibrosis through multiple mechanisms, at least partially by directly targeting HSC and by inhibiting the AMPK pathway. Its value as an antifibrotic drug in patients with liver disease deserves further investigation.

1. Introduction

Hepatic fibrosis is a common pathology in various progressive chronic liver diseases [1]. Fibrogenesis in liver, which often accompanies disease progression from hepatitis to cancerous transformation [2], is an abnormal process in which the organ develops excessive accumulation of extracellular matrix proteins in response to chronic injury [3]. Activation of hepatic stellate cells (HSC) is critical in the fibrogenic process of the liver and activated HSC are known as the main sources of a pathogenic extracellular matrix proteins in liver fibrosis [4, 5]. It is believed that effective treatment of hepatic fibrosis will be both crucial for the prevention of chronic liver failure and beneficial for the prevention of liver cancerous diseases [6]; however, there is still no standard treatment for liver fibrosis [7].

Berberine (BBR) is a natural alkaloid extracted from Coptidis Rhizoma (Huang Lian in Chinese), an herbal drug commonly used in traditional Chinese medicine for treating patients with inflammatory diseases. The major pharmacological actions of BBR may include antimicrobial [8], anti-inflammatory [9], antioxidative [10], and antitumoral activities [11]. Our previous studies have revealed the therapeutic effects of Coptidis Rhizoma and BBR on hepatocellular carcinoma, by inducing apoptotic and autophagic cell death at high doses [12] and by repressing tumor cell motility at lower doses [13]. These observations suggested that BBR be of potential value for treating liver malignancies [14]. Furthermore, it was also found by our group that extract of Coptidis Rhizoma exerted potent protective effect on acute and chronic liver damage in an experimental animal model of liver injury, significantly improving liver function and tissue structure [15, 16]. We further reported that, BBR, a major active compound extracted from Coptidis Rhizoma also protected animal from acute hepatic damage [17, 18]. BBR is able to reduce sustained and chronic liver injury in various animal models of hepatic damage [19]. We have proposed that BBR as an antifibrotic drug and its mechanisms of action are worth further investigation [20].

In this study, we aimed to investigate the in vitro and in vivo antifibrotic effect of BBR and its potential mechanisms with focus on HSC. The antifibrotic activity of BBR was evaluated in bile duct ligation-induced hepatic fibrosis model in rats. The action of BBR on activated HSC was investigated at both nontoxic and toxic levels. Understanding the action and mechanism of BBR in inhibiting hepatic fibrosis may shed light on the further development of antifibrotic treatment.

2. Materials and Methods

2.1. Chemicals and Reagents

BBR hydrochloride and Compound C, an AMPK inhibitor, were purchased from Sigma-Aldrich (USA).

2.2. Animals

Male SD rats of 220~250 g body weight were purchased from Guangdong Medical Laboratory Animal Centre, Guangzhou, Guangdong Province, China. Animals were housed at °C, with a 12 h light cycle, starting at 06:00, and were provided free access to standard laboratory chow and water. All experiments were approved by the ethics committee of the University of Hong Kong and complied with international guidelines.

2.3. Animal Model

Bile duct ligation (BDL) was applied to rats to induce extrahepatic cholestasis-related liver fibrosis. Briefly, under anaesthesia with ether, rats were subjected to ligation of the common bile duct with 3-0 silk and sectioned between the ligatures. The abdominal midline was then closed with catgut. Rats in a sham control group had their bile duct exposed with neither ligation nor sectioning. All rats were caged at 24°C with 12 h : 12 h light-dark cycle and were provided free access to food and water for 7 days before the study. All operated rats except sham controls were randomised into different groups.

2.4. Animal Treatment

Rats in sham and model groups received 10 mL/kg of distilled water per day by oral administration. Rats in BBR treatment group received 120 mg/kg/day BBR dissolved in distilled water orally. All treatment lasted for seven weeks.

2.5. Biochemical Analysis

At the end of the experiment, animals were sacrificed by i.p. injection of 200 mg/kg pentobarbitone. Blood was collected and serum was separated by centrifugation at 3000 g for 5 min. Serum AST, ALT, and TBil were quantified by a biochemical autoanalyzer. The tissue hydroxyproline (HyP) level was examined with a HyP detection kit (Jiancheng Bioengineering Institute, Nanjing, China) following the manufacturer’s instructions.

2.6. Histological Analysis

Livers collected from different groups of rats were rinsed with PBS and fixed in 4% buffered formaldehyde for 24 h. Paraffin-embedded tissues were cut into 5 μm sections and stained with hematoxylin and eosin (H&E). To evaluate chronic liver injury by a semiquantitative scoring, five phases of liver injury were defined as follows: S0: no observable scaring; S1: no extended portal area scaring; S2: fibrotic portal area with intact lobule structure; S3: fibrosis with broken lobule structure and no cirrhosis; and S4: cirrhosis. Fibrotic area within 1.5 mm2 of each section was measured. Images were captured under light microscope (Leica Microsystems Digital Imaging, Germany) with CCD camera at the magnification of (Leica DFC 280, Germany).

2.7. Cells and Cell Culture

The human hepatocyte cell line L-02 and human HSC line hHS were obtained from Sun Yat-Sen University (Guangdong, China). The cells were cultured in Dulbecco’s Modified Eagle medium with high glucose (4.5 g/L) with supplements of 10% Foetal Bovine Serum (FBS) and 1% penicillin/streptomycin and incubated in a humidified atmosphere containing 5% CO2 at 37°C.

2.8. Cell Viability Assay

Cell viability assay was performed to examine the cytotoxicity of BBR to HSC cells. Briefly, cells were cultured in 96-well cell culture plate in DMEM supplemented with 10% FBS. Each well contained 10,000 cells for attachment overnight. A series of concentrations of BBR were added to the cells to incubate. Then, 10 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL, Sigma, USA) was added to each well 4 h before the end of treatment and the incubation was continued at 37°C. The medium was then discarded and 100 μL DMSO was added to dissolve the crystals with gentle pipetting. The absorbance was read at 575 nm on a Multiskan MS Microplate Reader (Labsystems, Finland).

2.9. Annexin V and Propidium Iodide (PI) Staining

Annexin V and PI double staining was introduced to analyze cell apoptosis and necrosis. In brief, cells were trypsinized, collected, and centrifuged. Cells were stained using the Annexin V and PI double staining kit (Sigma-Aldrich, USA) in binding buffer containing 100 mM HEPES/NaOH, 1.4 mM NaCl, and 25 mM CaCl2, pH 7.5. Five μL 50 μg/mL FITC-conjugated Annexin V and 10 μL 100 μg/mL PI were added and samples were incubated in dark at room temperature for 15 min. The cell suspension was then detected by flow cytometer (Epics XL, Beckman Coulter, USA). Results were analyzed with the FlowJo software (USA).

2.10. Transwell Migration Assay

hHSC motility upon BBR treatment was examined in Millicell-PCF Cell Culture Insert (24-well, 8.0 μm, Millipore). Briefly, the inserts were standing in 24-well cell culture plate. cells in 100 μL serum-free medium were added to the insert, while 0.5 mL 10% FBS DMEM containing indicated concentrations of BBR was added to each well of the 24-well plate. This was followed by incubation in 5% CO2 at 37°C for 24 hr. The noninvading cells on the upper surface were removed by cotton swabs. The cells that invaded across the transmembrane to the lower surface of the membrane were fixed by ice cool 100% ethanol and stained by 2% crystal violet (Sigma-Aldrich, USA). Photographs of the stained migrated cells (3 random fields per culture) were taken under an inverted microscope at 400× and the mean number of cells of the 3 fields was recorded.

2.11. JC-1 Staining

The measurement of mitochondrial membrane potential was conducted with JC-1 staining. Cells were seeded in 35 mm glass-bottom dishes and treated with BBR. Cells were then stained with 10 μg/mL JC-1 (Invitrogen, USA) in dark for 30 min and visualized under a fluorescence microscope. Intense red fluorescence indicates the integrity of mitochondrial membrane, while increased green fluorescence represents loss of mitochondrial membrane potential.

2.12. Immunofluorescence

Cells were seeded in 35 mm glass-bottom dishes and treated with BBR. The cells were then fixed with 4% paraformaldehyde in PBS followed by incubation with blocking buffer (5% normal goat serum and 0.03% Triton X-100 in PBS). Then, cells were incubated with antibody against α-SMA at 4°C overnight followed by wash. Alexa Fluor-conjugated secondary antibody (Invitrogen, USA) was added and cells were incubated in dark for 60 min. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). The cells were observed under fluorescence microscope (Carl Zeiss, USA) and images were captured with a CCD camera (400× magnification).

2.13. Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was extracted with total RNA purification kit (Norgen, Canada). cDNA was generated with first-strand cDNA synthesis kit (Roche, USA) using the collected RNA as template. The quantitative PCR was conducted with SYBR Green I master mix (Roche, USA) on LightCycler 480 (Roche, USA). The primer sequences of target genes were listed in Table 1.



2.14. Immunoblotting

Cells were lysed with the Radioimmunoprecipitation Assay (RIPA) Buffer with the cOmplete Cocktail Proteinase Inhibitor (Roche, USA) and phosphatase inhibitor (1 mM Na3VO4 and 1 mM NaF) on ice for 30 min followed by centrifugation at 14,000 rpm at 4°C for 15 min. Supernatants were transferred and protein concentrations were determined by BSA assay (Bio-Rad, USA). Equal yield of protein was separated on SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (PVDF, Bio-Rad). The membrane was then blocked in buffer containing 5% BSA, Tris (10 mmol/L, pH 7.4), NaCl (150 mmol/L), and Tween 20 (1%) at room temperature for 1 hr with gentle shaking. The membrane was then incubated with primary antibodies at 4°C overnight followed by incubation with appropriate secondary antibody (Abcam, UK) at room temperature for 1 hr. The immunoreactivities were detected using ECL advanced kit (GE Healthcare, UK) and visualized using a chemiluminescence imaging system (Bio-Rad, USA).

2.15. Statistical Analysis

Data were expressed as mean ± standard deviation of means (SD) and statistical comparisons were conducted using one-way ANOVA. value lower than 0.05 was considered statistically significant.

3. Results

3.1. BBR Suppressed BDL-Induced Hepatic Fibrosis in Rats

In the present study, hepatic fibrosis was induced by BDL in rats to induce extrahepatic cholestasis. Significant serum ALT and AST elevation was observed in BDL rats and BBR treatment remarkably reduced serum ALT and AST (Figure 1(a)). Content of HyP in the liver, as a biomarker of hepatic fibrosis, was measured, and BBR potently reduced the liver content of HyP consistently (Figure 1(b)) and reduced serum total bile acid level (Figure 1(c)). Histological analysis revealed that administration of BBR attenuated the hepatic fibrosis induced by BDL in rats (Figure 1(d)). Overall scores of liver fibrosis in different groups are shown in Table 2.

GroupSample ()Fibrosis stageFibrotic area within 1.5 mm2

Shammed6600000.007 0.005
Model6011310.079 0.025
BBR (120 mg/kg)6032100.032 0.024

: , : versus shammed group; #: versus model group.
3.2. Toxic Doses of BBR Induced Mitochondrial Apoptosis of HSC through Altering Bcl-2/Bax Ratio and Subsequent Caspase Activation

To explore possible mechanisms of the antifibrotic effect of BBR, we focused on the HSC, which are activated during fibrogenic process. hHSC, a constitutively activated human HSC line, was used to evaluate the cytotoxicity of BBR. High dose of BBR exhibited toxic effects to hHSC (IC50 75 μM, Figure 2(a)). Toxic dose of BBR could initiate apoptosis of hHSC (Figure 2(b)). This effect may be due to the increased permeability of mitochondrial membrane in hHSC with exposure of toxic dose of BBR (Figure 2(c)), which was indicated by the loss of mitochondrial membrane integrity. Expression of Bcl-2 was significantly downregulated upon BBR treatment, leading to Bcl-2/Bax imbalance and mitochondrial membrane polarization (Figure 2(d)). This observation was further confirmed by the release of cytochrome C into cytoplasm, which initiated caspase activation subsequently (Figure 2(d)). These results suggest that toxic dose of BBR may induce mitochondrial apoptosis in hHSC.

3.3. Nontoxic Doses of BBR Suppress HSC Activation by Inhibiting α-SMA Expression and Cell Migration

The toxic dose of BBR on normal hepatic cell line L-02 was examined to evaluate its possible adverse effect. It was shown that the IC50 value of BBR on L-02 cells was about 250 μM, indicating that high doses of BBR may exhibit some toxic action to normal hepatocytes (Figure 3(a)). Further examining the effect of BBR on HSC at nontoxic doses, we found that BBR significantly downregulated the expression of α-SMA, the biomarker of HSC activation, indicating that BBR might inactivate the activated hHSC at nontoxic doses (Figure 3(b)). Furthermore, BBR significantly downregulated hHSC motility (Figure 3(c)).

3.4. BBR Repressed α-SMA and Collagen mRNA Expression without Altering Smad2/3 Phosphorylation

The TGF-β/Smad signalling plays an important role in HSC activation in liver fibrosis [21]. As BBR was reported to suppress TGF-β expression in the plasma of patients with lung cancer who were undergoing radiotherapy [22], the expression of TGF-β was analyzed in our study to prove if similar action of BBR could be found. However, in our study, we observed no significant reduction of TGF-β expression in BBR-treated hHSC (Figure 4(a)). Neither did BBR suppress Smad2/3 phosphorylation (Figure 4(b)). However, BBR dose-dependently inhibited the mRNA expression of α-SMA (ACTA2), collagen 1A (COL1A1), and collagen IV (COL4A3) (Figure 4(c)).

3.5. AMPK Activation Is Responsible for the Smad2/3 Inhibition by BBR in HSC

Activation of AMPK signalling by BBR was observed in hHSC (Figure 5(a)). Previous studies have exhibited the role of AMPK activation in the treatment against oxidative stress-induced liver injury [23] and it was shown that AMPK activity is critical for the experimental therapy of hepatic fibrosis as well [24]. In our study, further examination was made to explore the role of AMPK activation in BBR’s inhibitory effect of experimental hepatic fibrosis. BBR suppression of α-SMA, COL1A1, and COL4A3 mRNA in hHSC was potently attenuated by the presence of Compound C, an AMPK inhibitor (Figure 5(b)), suggesting that BBR suppression of these mRNAs might be attributed to AMPK activation in hHSC. A critical role for AMPK in BBR repression of hHSC activation was further confirmed by the fact that BBR repression of α-SMA expression and hHSC motility were both prevented by Compound C (Figures 5(c) and 5(d)).

4. Discussion

Critical role of HSC activation in the early development of liver fibrosis has been revealed by previous studies [25]. The activation of HSC initiates its proliferation as well as the production of extracellular matrix (ECM) proteins such as α-SMA and collagens [6]. Attempts have been made to explore the use of BBR in the therapy for fibrosis-related hepatic diseases. Previous studies have shown that BBR could be used for the treatment against hypertyraminemia in patients with liver cirrhosis [26], which was correlated with BBR’s capacity of reducing blood lipid in hyperlipidemic patients [27]. Experimental studies have been also conducted, the results of which exhibit the potential of BBR in ameliorating hepatic fibrosis with various mechanisms [28, 29]. In particular, it was shown that the antioxidative activity of BBR contributes to improvement of experimental hepatic fibrosis via stimulating matrix metalloproteinase-2 (MMP-2) [30]. Our findings further showed that apoptosis of HSC could be initiated by toxic doses of BBR, and Bcl-2/Bax-mediated mitochondrial membrane potential loss may be involved in induction of HSC apoptosis by BBR. Interestingly, we found that nontoxic doses of BBR downregulated the activation of HSC, suppressing production of ECM proteins, preventing deregulation of hepatic architecture and protecting hepatocytes from hepatocellular dysfunction (Figure 6) [31].

It has been previously shown that the activity of AMPK signalling is a critical factor in the prevention of hepatic fibrogenesis. In AMPK-deficient mice, the fibrogenesis and liver fibrosis could be enhanced dramatically, and initiation of AMPK could suppress HSC proliferation and collagen expression [31]. The preventive effect of AMPK on hepatic fibrosis was further evidenced by the fact that an adipocytokine adiponectin could disrupt leptin-mediated hepatic fibrosis through the activation of AMPK in HSC [24]. A recent study showed that berberine can replenish the activity of AMPK in the liver of carbon tetrachloride- (CCl4) treated mice [32]; however, whether activation of AMPK by berberine is responsible for the improvement of experimental fibrosis remains not clear. Furthermore, whether activation of AMPK by berberine can suppress activated hepatic stellate cells, which majorly mediates fibrogenesis in the liver, was not studied. In our study, we observed that hepatic fibrosis induced by BDL could be attenuated by BBR, which in hHSC activates AMPK signalling and inhibits hHSC migration and α-SMA production. Inhibition of AMPK by Compound C potently reduced the inhibitory effect on hHSC activation, which was evidenced by the fact that cell motility and α-SMA expression were restored in BBR-treated cells in the presence of Compound C. These findings support a central role of AMPK activation in BBR’s effect on HSC activation and subsequent fibrogenesis.

We noticed that BBR has no effect on the signal transduction of TGF-β/Smad. BBR neither suppresses the TGF-β expression in HSC nor inhibits Smad2/3 phosphorylation. However, the expression of profibrogenic factors α-SMA, COL1A1, and COL4A3 was inhibited by BBR and this effect could be attenuated by inhibition of AMPK by Compound C. These observations indicate that activation of AMPK could repress fibrogenesis without affecting Smad2/3 phosphorylation. A previous study showed that transcription activity mediated by Smad2/3 requires cooperation of transcription coactivators CBP and p300, which initiate the N-terminal acetylation of Smad2/3 [33, 34]. Phosphorylated AMPK was reported to bind with p300, initiate its proteasomal degradation, and consequently inhibit Smad2/3 transcription activity without affecting their phosphorylation [35]. Deletion of p300 has been found to suppress fibrogenic collagen type I and α-SMA expression and lead to fibrogenesis inhibition [35, 36]. Our findings on the critical role for BBR activation of AMPK in HSC shed light on the antifibrotic action of BBR and support its potential value for the treatment of fibrosis in liver disease.

5. Conclusion

BBR is a promising agent for treating liver fibrosis through multiple mechanisms, at least partially by directly targeting HSC and by inhibiting the AMPK pathway. Its value as an antifibrotic drug in patients with liver disease deserves further investigation.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Ning Wang did the experiments and drafted the paper. Qihe Xu provided guidance on fibrosis models and antifibrotic assays. All authors revised and commented on the paper and discussed the paper. Yibin Feng conceived and designed the project and finalized the paper.


This research was partially supported by the research council of the University of Hong Kong (Project Codes: 104002889 and 104003422), Wong’s donation (Project Code: 200006276), the donation of Gaia Family Trust, New Zealand (Project Code: 200007008), National Natural Science Foundation of China (Project Code: 81302808), and the Research Grant Committee (RGC) of Hong Kong (RGC General Research Fund, Project Code: 10500362).


  1. G. Shiha, S. K. Sarin, A. E. Ibrahim et al., “Liver fibrosis: consensus recommendations of the Asian Pacific association for the study of the liver (APASL),” Hepatology International, vol. 3, no. 2, pp. 323–333, 2009. View at: Publisher Site | Google Scholar
  2. M. Kukla, “Angiogenesis: a phenomenon which aggravates chronic liver disease progression,” Hepatology International, vol. 7, no. 1, pp. 4–12, 2013. View at: Publisher Site | Google Scholar
  3. H. Hayashi and T. Sakai, “Animal models for the study of liver fibrosis: new insights from knockout mouse models,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 300, no. 5, pp. G729–G738, 2011. View at: Publisher Site | Google Scholar
  4. S. L. Friedman, “Mechanisms of hepatic fibrogenesis,” Gastroenterology, vol. 134, no. 6, pp. 1655–1669, 2008. View at: Publisher Site | Google Scholar
  5. V. Hernandez-Gea and S. L. Friedman, “Pathogenesis of liver fibrosis,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 425–456, 2011. View at: Publisher Site | Google Scholar
  6. S. L. Friedman, “Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver,” Physiological Reviews, vol. 88, no. 1, pp. 125–172, 2008. View at: Publisher Site | Google Scholar
  7. K. Cheng and R. I. Mahato, “Gene modulation for treating liver fibrosis,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 24, no. 2, pp. 93–146, 2007. View at: Publisher Site | Google Scholar
  8. G. Lei, H. Dan, L. Jinhua, Y. Wei, G. Song, and W. Li, “Berberine and itraconazole are not synergistic in vitro against aspergillus fumigatus isolated from clinical patients,” Molecules, vol. 16, no. 11, pp. 9218–9233, 2011. View at: Publisher Site | Google Scholar
  9. X.-H. Wang, S.-M. Jiang, and Q.-W. Sun, “Effects of berberine on human rheumatoid arthritis fibroblast-like synoviocytes,” Experimental Biology and Medicine, vol. 236, no. 7, pp. 859–866, 2011. View at: Publisher Site | Google Scholar
  10. S. Kim, Y. Kim, J. E. Kim, K. H. Cho, and J. H. Chung, “Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes,” Phytomedicine, vol. 15, no. 5, pp. 340–347, 2008. View at: Publisher Site | Google Scholar
  11. J. Tang, Y. Feng, S. Tsao, N. Wang, R. Curtain, and Y. Wang, “Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations,” Journal of Ethnopharmacology, vol. 126, no. 1, pp. 5–17, 2009. View at: Publisher Site | Google Scholar
  12. N. Wang, Y. Feng, M. Zhu et al., “Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism,” Journal of Cellular Biochemistry, vol. 111, no. 6, pp. 1426–1436, 2010. View at: Publisher Site | Google Scholar
  13. N. Wang, Y. Feng, E. P. W. Lau et al., “F-actin reorganization and inactivation of Rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration,” Integrative Cancer Therapies, vol. 9, no. 4, pp. 354–364, 2010. View at: Publisher Site | Google Scholar
  14. Y. Feng, N. Wang, M. Zhu, Y. Feng, H. Li, and S. Tsao, “Recent progress on anticancer candidates in patents of herbal medicinal products,” Recent Patents on Food, Nutrition and Agriculture, vol. 3, no. 1, pp. 30–48, 2011. View at: Publisher Site | Google Scholar
  15. X. Ye, Y. Feng, Y. Tong et al., “Hepatoprotective effects of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats,” Journal of Ethnopharmacology, vol. 124, no. 1, pp. 130–136, 2009. View at: Publisher Site | Google Scholar
  16. Y. Feng, N. Wang, X. Ye et al., “Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats,” Journal of Ethnopharmacology, vol. 138, no. 3, pp. 683–690, 2011. View at: Publisher Site | Google Scholar
  17. Y. Feng, K.-Y. Siu, X. Ye et al., “Hepatoprotective effects of berberine on carbon tetrachloride-induced acute hepatotoxicity in rats,” Chinese Medicine, vol. 5, article 33, 2010. View at: Publisher Site | Google Scholar
  18. X. Zhao, J. Zhang, N. Tong, Y. Chen, and Y. Luo, “Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice,” Biological and Pharmaceutical Bulletin, vol. 35, no. 5, pp. 796–800, 2012. View at: Publisher Site | Google Scholar
  19. N. Wang, Y. Feng, F. Cheung et al., “A comparative study on the hepatoprotective action of bear bile and coptidis rhizoma aqueous extract on experimental liver fibrosis in rats,” BMC Complementary and Alternative Medicine, vol. 12, article 239, 2012. View at: Publisher Site | Google Scholar
  20. Y. Feng, K.-F. Cheung, N. Wang, P. Liu, T. Nagamatsu, and Y. Tong, “Chinese medicines as a resource for liver fibrosis treatment,” Chinese Medicine, vol. 4, article 16, 2009. View at: Publisher Site | Google Scholar
  21. E. Piek, C.-H. Heldin, and P. T. Dijke, “Specificity, diversity, and regulation in TGF-β superfamily signaling,” The FASEB Journal, vol. 13, no. 15, pp. 2105–2124, 1999. View at: Google Scholar
  22. Y. Liu, H. Yu, C. Zhang et al., “Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer,” European Journal of Cancer, vol. 44, no. 16, pp. 2425–2432, 2008. View at: Publisher Site | Google Scholar
  23. Y. W. Kim, S. M. Lee, S. M. Shin et al., “Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury,” Free Radical Biology and Medicine, vol. 47, no. 7, pp. 1082–1092, 2009. View at: Publisher Site | Google Scholar
  24. J. A. Handy, N. K. Saxena, P. Fu et al., “Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3),” Journal of Cellular Biochemistry, vol. 110, no. 5, pp. 1195–1207, 2010. View at: Publisher Site | Google Scholar
  25. R. Bataller and D. A. Brenner, “Liver fibrosis,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005. View at: Publisher Site | Google Scholar
  26. A. Watanabe, T. Obata, and H. Nagashima, “Berberine therapy of hypertyraminemia in patients with liver cirrhosis,” Acta Medica Okayama, vol. 36, no. 4, pp. 277–281, 1982. View at: Google Scholar
  27. W. Zhao, R. Xue, Z.-X. Zhou, W.-J. Kong, and J.-D. Jiang, “Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis,” Biomedicine and Pharmacotherapy, vol. 62, no. 10, pp. 730–731, 2008. View at: Publisher Site | Google Scholar
  28. B.-J. Zhang, D. Xu, Y. Guo, J. Ping, L.-B. Chen, and H. Wang, “Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 3, pp. 303–309, 2008. View at: Publisher Site | Google Scholar
  29. X. Sun, X. Zhang, H. Hu et al., “Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis,” Biological and Pharmaceutical Bulletin, vol. 32, no. 9, pp. 1533–1537, 2009. View at: Publisher Site | Google Scholar
  30. R. Domitrović, H. Jakovac, V. V. Marchesi, and B. Blažeković, “Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression,” Journal of Medicinal Food, vol. 16, no. 6, pp. 518–528, 2013. View at: Publisher Site | Google Scholar
  31. A. M. Gressner and R. Weiskirchen, “Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets,” Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 76–99, 2006. View at: Publisher Site | Google Scholar
  32. J. Li, Y. Pan, M. Kan et al., “Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase,” Life Sciences, vol. 98, no. 1, pp. 24–30, 2014. View at: Publisher Site | Google Scholar
  33. Y. Inoue, Y. Itoh, K. Abe et al., “Smad3 is acetylated by p300/CBP to regulate its transactivation activity,” Oncogene, vol. 26, no. 4, pp. 500–508, 2007. View at: Publisher Site | Google Scholar
  34. A. W. Tu and K. Luo, “Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor β response,” The Journal of Biological Chemistry, vol. 282, no. 29, pp. 21187–21196, 2007. View at: Publisher Site | Google Scholar
  35. J.-Y. Lim, M.-A. Oh, W. H. Kim, H.-Y. Sohn, and S. I. Park, “AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300,” Journal of Cellular Physiology, vol. 227, no. 3, pp. 1081–1089, 2012. View at: Publisher Site | Google Scholar
  36. S. Yavrom, L. Chen, S. Xiong, J. Wang, R. A. Rippe, and H. Tsukamoto, “Peroxisome proliferator-activated receptor γ suppresses proximal α1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells,” The Journal of Biological Chemistry, vol. 280, no. 49, pp. 40650–40659, 2005. View at: Publisher Site | Google Scholar

Copyright © 2016 Ning Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.